...
首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Plasma MicroRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer
【24h】

Plasma MicroRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer

机译:血浆MicroRNAs作为子宫内膜异位症和与子宫内膜异位症相关的卵巢癌的新型生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Endometriosis, a largely benign, chronic inflammatory disease, is an independent risk factor for endometrioid and clear cell epithelial ovarian tumors.Weaimed to identify plasma miRNAs that can be used to differentiate patients with endometriosis and ovarian cancer from healthy individuals. Experimental Design: We conducted a two-stage exploratory study to investigate the use of plasma miRNA profiling to differentiate between patients with endometriosis, patients with endometriosisassociated ovarian cancer (EAOC), and healthy individuals. In the first stage, using global profiling of more than 1,000 miRNAs via reverse transcriptase quantitative PCR (RT-qPCR) in a 20-patient initial screening cohort, we identified 23 candidate miRNAs, which are differentially expressed between healthy controls (n = 6), patients with endometriosis (n = 7), and patients with EAOC (n = 7) based on the fold changes. In the second stage, the 23 miRNAs were further tested in an expanded cohort (n = 88) of healthy individuals (n=20), endometriosis (n=33), EAOC(n=14), and serous ovarian cancer cases (SOC; n=21, included as controls). Results: We identified three distinct miRNA signatures with reliable differential expression between healthy individuals, patients with endometriosis, and patients with EAOC. When profiled against the control SOC category, our results revealed different miRNAs, suggesting that the identified signatures are reflective of disease-specific pathogenic mechanisms. This was further supported by the fact that the majority of miRNAs differentially expressed in human EAOCs were mirrored in a double transgenic mouse EAOC model. Conclusion: Our study reports for the first time that distinct plasma miRNA expression patterns may serve as highly specific and sensitive diagnostic biomarkers to discriminate between healthy, endometriosis, and EAOC cases.
机译:目的:子宫内膜异位症是一种良性的慢性炎症性疾病,是子宫内膜样和透明细胞上皮性卵巢癌的独立危险因素。我们旨在鉴定血浆miRNA,可用于区分健康人群和子宫内膜异位症和卵巢癌患者。实验设计:我们进行了两阶段的探索性研究,以研究血浆miRNA分析在区分子宫内膜异位症患者,子宫内膜异位症相关卵巢癌(EAOC)患者和健康个体之间的区别。在第一阶段中,在20位患者的初始筛查队列中,通过逆转录酶定量PCR(RT-qPCR)对1,000多种miRNA进行了全局分析,我们鉴定了23种候选miRNA,它们在健康对照组之间差异表达(n = 6) ,子宫内膜异位患者(n = 7)和EAOC患者(n = 7)基于倍数变化。在第二阶段,在健康人群(n = 20),子宫内膜异位症(n = 33),EAOC(n = 14)和浆液性卵巢癌病例(SOC)的扩大队列(n = 88)中进一步测试了23种miRNA。 ; n = 21,作为控件包含在内)。结果:我们鉴定出三个独特的miRNA标记,这些标记在健康个体,子宫内膜异位症患者和EAOC患者之间具有可靠的差异表达。当对照对照SOC类别进行分析时,我们的结果显示了不同的miRNA,这表明所识别的特征反映了疾病特异性的致病机制。事实证明,在人类EAOC中差异表达的大多数miRNA在双转基因小鼠EAOC模型中得到了反映。结论:我们的研究首次报道了不同的​​血浆miRNA表达模式可作为区分健康,子宫内膜异位和EAOC病例的高度特异性和敏感的诊断生物标志物。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号